1. Home
  2. ACV vs PBYI Comparison

ACV vs PBYI Comparison

Compare ACV & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Diversified Income & Convertible Fund of Beneficial Interest

ACV

Virtus Diversified Income & Convertible Fund of Beneficial Interest

HOLD

Current Price

$27.35

Market Cap

272.3M

Sector

Finance

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$6.39

Market Cap

263.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACV
PBYI
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
272.3M
263.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ACV
PBYI
Price
$27.35
$6.39
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
38.8K
368.1K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
9.20%
N/A
EPS Growth
N/A
59.87
EPS
N/A
0.74
Revenue
N/A
$211,995,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.56
Revenue Growth
N/A
N/A
52 Week Low
$16.82
$2.58
52 Week High
$23.74
$6.48

Technical Indicators

Market Signals
Indicator
ACV
PBYI
Relative Strength Index (RSI) 62.65 64.96
Support Level $27.09 $6.05
Resistance Level $27.79 $6.29
Average True Range (ATR) 0.45 0.23
MACD 0.04 0.02
Stochastic Oscillator 40.29 86.12

Price Performance

Historical Comparison
ACV
PBYI

About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest

Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: